XML 51 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Tables)
12 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of exercisable share purchase warrants outstanding
           
      Weighted
      Average
      Exercise Price
   Number of Shares  ($)
Balance, September 30, 2019    350,000    4.19 
Granted    150,000    3.17 
Balance, September 30, 2020    500,000    3.88 
Granted    60,000    12.00 
Exercised    (350,000)   4.19 
Balance, September 30, 2021    210,000    5.69 

Schedule of share purchase warrants outstanding
            
Number  Exercise Price  Expiry Date
 150,000   $3.17    May 6, 2024 
 60,000   $12.00    April 21, 2026 
 210,000         

Schedule of outstanding stock purchase options
                     
         Weighted   
      Weighted  Average Grant  Aggregate
      Average Exercise  Date Fair  intrinsic value
   Number of Shares  Price ($)  Value ($)  ($)
Outstanding, September 30, 2019    8,462,933    3.58         4,115,032 
Granted    1,695,000    2.96    2.27      
Forfeited    (68,332)   3.01    2.44      
Exercised    (13,335)   3.15    2.61    2,400 
Outstanding, September 30, 2020    10,076,266    3.48         14,982,581 
Granted    2,732,000    12.55    9.32      
Forfeited    (55,834)   3.04    2.43      
Exercised    (1,421,529)   2.89    2.43    24,446,305 
Outstanding, September 30, 2021    11,330,903    5.74         140,132,451 
Exercisable, September 30, 2021    7,228,488    3.73         102,786,851 
Summarizes information about stock options
                                
      Number of  Weighted average remaining  Weighted average  Number of  Weighted average
Range of exercise prices  outstanding  contractual life  exercise  vested  exercise
From  To  options  (in years)  price  options  price
$0.92   $2.96    4,309,349    6.25    2.31    3,167,682    2.10 
$3.15   $4.80    2,117,500    6.33    3.30    1,830,836    3.29 
$5.04   $8.98    3,397,054    6.45    6.05    2,207,054    6.35 
$12.00   $13.01    230,000    9.52    12.44    22,916    12.42 
$18.11   $24.58    1,277,000    9.82    19.33         
           11,330,903              7,228,488      

Schedule of general and administrative expenses and research and development expenses
          
   2021  2020
General and administrative  $3,571,335   $2,210,789 
Research and development  $4,660,068   $2,666,117 
Total stock-based compensation  $8,231,403   $4,876,906 

Schedule of weighted average assumptions for fair value of each option award
          
   2021  2020
Risk-free interest rate   0.73%   1.57%
Expected life of options (years)   5.74    5.53 
Annualized volatility   93.43%   95.99%
Dividend rate   0.00%   0.00%